1.6(top 50%)
impact factor
647(top 20%)
papers
6.6K(top 20%)
citations
35(top 20%)
h-index
1.8(top 50%)
impact factor
801
all documents
7.3K
doc citations
52(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updatesChinese Clinical Oncology2018142
2Biliary carcinomas: pathology and the role of DNA mismatch repair deficiencyChinese Clinical Oncology2016131
3Advanced magnetic resonance imaging in glioblastoma: a reviewChinese Clinical Oncology2017119
4The emerging role of oncolytic virus therapy against cancerChinese Clinical Oncology2018105
5Epidemiology of ovarian cancerChinese Clinical Oncology2020101
6Staging and response assessment in lymphomas: the new Lugano classificationChinese Clinical Oncology201599
7Genetic and epigenetic landscape of nasopharyngeal carcinomaChinese Clinical Oncology201694
8Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associationsChinese Clinical Oncology201694
9Epidemiology of gallbladder cancer in IndiaChinese Clinical Oncology201990
10Gallbladder cancer: epidemiology and genetic risk associationsChinese Clinical Oncology201989
11A review of hepatocellular carcinoma (HCC) staging systemsChinese Clinical Oncology201370
12Advances in systemic treatment for nasopharyngeal carcinomaChinese Clinical Oncology201669
13Classification of meningiomas—advances and controversiesChinese Clinical Oncology201766
14Immunotherapy for metastatic breast cancerChinese Clinical Oncology201866
15Immunotherapy for nasopharyngeal cancer—a reviewChinese Clinical Oncology201660
16Systemic therapy for esophageal cancer: chemotherapyChinese Clinical Oncology201755
17An overview of the NCI precision medicine trials-NCI MATCH and MPACTChinese Clinical Oncology201553
18Thermal ablation for hepatocellular carcinoma: what’s new in 2019Chinese Clinical Oncology201951
19Cost-comparativeness of proton versus photon therapyChinese Clinical Oncology201651
20The inflammatory microenvironment in brain metastases: potential treatment target?Chinese Clinical Oncology201551
21Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinomaChinese Clinical Oncology201647
22MicroRNAs in nasopharyngeal carcinomaChinese Clinical Oncology201647
23Systemic therapy for hepatocellular carcinoma: beyond sorafenibChinese Clinical Oncology201847
24Prognostic scores for brain metastasis patients: use in clinical practice and trial designChinese Clinical Oncology201547
25Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Chinese Clinical Oncology201646
26The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancerChinese Clinical Oncology201545
27Neoadjuvant treatment for HER2-positive breast cancerChinese Clinical Oncology202044
28Preclinical models of pancreatic ductal adenocarcinomaChinese Clinical Oncology201744
29Precision medicine in breast cancerChinese Clinical Oncology201844
30BRAF, MEK and KIT inhibitors for melanoma: adverse events and their managementChinese Clinical Oncology201444
31Proton therapy for the management of uveal melanoma and other ocular tumorsChinese Clinical Oncology201642
32Pathologic classification of “pancreatic cancers”: current concepts and challengesChinese Clinical Oncology201742
33Reirradiation of locally recurrent nasopharyngeal cancer: history, advances, and promises for the futureChinese Clinical Oncology201641
34Management of fibrolamellar hepatocellular carcinomaChinese Clinical Oncology201840
35Gallbladder cancer: surgical managementChinese Clinical Oncology201939
36New approaches in primary central nervous system lymphomaChinese Clinical Oncology201539
37An overview of the design and conduct of the BATTLE trialsChinese Clinical Oncology201539
38Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)Chinese Clinical Oncology202038
39Update on skin directed therapies in mycosis fungoidesChinese Clinical Oncology201938
40Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancerChinese Clinical Oncology202037
41Surgical margins in the management of extremity soft tissue sarcomaChinese Clinical Oncology201836
42Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition)Chinese Clinical Oncology201236
43Genetic susceptibility to the endemic form of NPCChinese Clinical Oncology201635
44Risk factors for developing hepatocellular carcinoma in EgyptChinese Clinical Oncology201335
45Primary extranodal B-cell lymphoma: current concepts and treatment strategiesChinese Clinical Oncology201535
46Epidemiology of pancreatic adenocarcinomaChinese Clinical Oncology201734
47Proton therapy for nasopharyngeal carcinomaChinese Clinical Oncology201633
48Combined intrahepatic cholangiocarcinoma and hepatocellular carcinomaChinese Clinical Oncology201633
49Systemic therapy of cutaneous T-cell lymphoma (CTCL)Chinese Clinical Oncology201933
50Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profilingChinese Clinical Oncology201933